The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models

Eri Shiraishi, Kazunori Suzuki, Akina Harada, Noriko Suzuki, and Haruhide Kimura

*CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan*

Journal of Pharmacology and Experimental Therapeutics

**Supplemental Fig. 1**

**A** Rat

**B** Mouse

Supplemental Fig. 1. The effect of TAK-063 on locomotor activity in a novel environment in male SD rats (A) or ICR mice (B). After a pretreatment time, animals were transferred to the test chamber. Accumulated activity counts during the 120 min were calculated and are indicated as mean ± SEM (n = 6 in rats, n = 10 in mice). There was no significant difference between the groups by two-tailed Williams's test (P > 0.05).